Sugi Predict

Sugi Predict / Compounds / SCHEMBL5175290

SCHEMBL5175290

SCHEMBL5175290

O=C(O)N1C2CCC1CN(Cc1ccccc1)C2

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ S1PR5 Q9H228 3/20 0.54
▸ S1PR1 P21453 1/20 0.54
▸ OPRM1 P35372 1/20 0.54
▸ FUCA1 P04066 2/20 0.53
▸ ALDH1A1 P00352 1/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ GRIN2B Q13224 1/20 0.47
▸ DRD2 P14416 1/20 0.47
▸ DRD4 P21917 1/20 0.47
▸ DRD3 P35462 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ SIGMAR1 Q99720 1/20 0.47
▸ BCHE P06276 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17512633 1.00 S1PR5 (0.54) S1PR5S1PR1OPRM1FUCA1ALDH1A1
SCHEMBL742934 0.87 S1PR5 (0.51) S1PR5S1PR1OPRM1FUCA1
SCHEMBL18446002 0.86 S1PR5 (0.51) S1PR5SIGMAR1
SCHEMBL9686795 0.84 OPRM1 (0.49) S1PR5S1PR1OPRM1FUCA1ALDH1A1
Hydrochloric Acid SCHEMBL9687011 0.83 OPRM1 (0.48) S1PR5S1PR1OPRM1FUCA1ALDH1A1
SCHEMBL18711744 0.81 S1PR1 (0.49) S1PR5S1PR1OPRM1FUCA1ALDH1A1
SCHEMBL25325036 0.81 S1PR5 (0.46) S1PR5S1PR1OPRM1FUCA1ALDH1A1
SCHEMBL3322574 0.80 S1PR5 (0.54) S1PR5S1PR1FUCA1ALDH1A1GRIN2B
SCHEMBL22569544 0.80 KCNK3 (0.52) S1PR5S1PR1OPRM1KMT2A
SCHEMBL23053901 0.80 KCNK3 (0.52) S1PR5S1PR1OPRM1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109714-A1 PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF GENFLEET THERAPEUTICS SHANGHAI INC (CN) 2026-04-23 — — US disclosed
EP-4592295-A1 PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2025-07-30 — — EP disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 — — US disclosed
WO-2023030385-A1 PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF 劲方医药科技(上海)有限公司 2023-03-09 — — WO disclosed
EP-1869050-A1 NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-12-26 — — EP disclosed
WO-2006106090-A1 NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2006-10-12 — — WO disclosed
US-7012074-B2 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2006-03-14 — — US disclosed
US-20050272745-A1 Novel piperidine and piperazine derivatives ASTRAZENECA AB 2005-12-08 — — US disclosed
US-6969713-B2 Piperidine and piperazine acetamide derivatives ASTRAZENECA AB (SE) 2005-11-29 — — US disclosed
US-6734306-B2 USEFUL IN THE TREATMENT OF INFLAMMATION, ASTHMA, ALLERGIC RHINITIS, PAIN OR THE LIKE PFIZER, INC. 2004-05-11 — — US disclosed
US-20040023971-A1 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2004-02-05 — — US disclosed
EP-1242427-B1 NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2003-08-13 — — EP disclosed
EP-1328526-A1 3,8-DIAZABICYCLO[3.2.1]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2003-07-23 — — EP disclosed
US-20020128271-A1 N-benzenesulfonyl l-proline compounds as bradykinin antagonists PFIZER INC. 2002-09-12 — — US disclosed
EP-1213289-A1 N-benzenesulfonyl L-proline compounds as bradykinin antagonists PFIZER INC. (US) 2002-06-12 — — EP disclosed
WO-2002032902-A1 3,8-DIAZABICYCLO[3.2.1]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2002-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272745-A1 Novel piperidine and piperazine derivatives CYP3A5, IL5, ABCC5 S1PR5 76/4885S1PR1 396/4885OPRM1 436/4885
US-20040023971-A1 3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias KCNH1, KCNH2, RYR2 S1PR5 1316/4885S1PR1 725/4885OPRM1 608/4885
US-20260109714-A1 PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF KRAS, NRAS, HRAS S1PR5 4478/4885S1PR1 4027/4885OPRM1 1240/4885
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT KRAS, NRAS, HRAS S1PR5 3072/4885S1PR1 2894/4885OPRM1 4761/4885
US-20020128271-A1 N-benzenesulfonyl l-proline compounds as bradykinin antagonists BDKRB1, HRH2, BDKRB2 S1PR5 568/4885S1PR1 467/4885OPRM1 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.